RTN is a collection of historically used tissue-based formulations, originally developed in Czechoslovakia in the 1940s. Administered in clinical settings to support oncology care, inflammation control, and tissue regeneration, these compounds are now being reintroduced under modern scientific and regulatory standards.
To bring validated, naturally derived compounds back into evidence-based healthcare—revitalizing decades of historical data with modern preclinical science to confirm their efficacy, safety, and relevance for today’s world.
RTN preparations used in over 12,000 documented hospital cases across Czechoslovakia.
State-approved and manufactured for national health programs.
Phased out due to synthetic pharmaceutical dominance, despite continued institutional support.
Scientific revival via EkoRTN, applying rigorous modern validation and regulatory compliance.
A nucleotide extract derived from bovine tissue, rich in ATP precursors (AMP, GMP, CMP). Supports cellular energy production and regeneration.
Phospholipid complex promoting vasodilation, nerve regeneration, and cellular membrane repair. Originally developed for frostbite, gangrene, and circulatory disorders.
Water-soluble extract of St. John’s Wort, purified for anti-inflammatory and antioxidant properties. Historical applications in gynecology, inflammation, and systemic oxidative stress.
Marine-derived preparation aimed at joint support, pain relief, and anti-inflammatory function. (in redevelopment)
All current formulations are undergoing controlled preclinical validation aligned with EU and international dietary supplement safety standards.
Custom sensors, open-source platforms, and secure digital infrastructure support continuous production monitoring for needed quality.
Our diagnostics platform uses structured biomarker data collection to inform product optimization and individual response tracking.
We match preparations to individuals based on advanced diagnostic panels. These include inflammation markers, lipid profiles, immune response indicators, and more.
We use AI tools to interpret complex biomarker data—these are designed to assist clinicians, not replace them. No magic, no hype.
Expanding our network with certified clinical and academic institutions to accelerate validation efforts.
Initiating Phase I trials with verified RTN preparations to establish safety profiles and preliminary efficacy data.
Documenting results in peer-reviewed journals to build credibility within the scientific community.
Securing regulatory recognition through rigorous documentation and compliance with FDA, EMA and Thai FDA authorities.
We're enrolling volunteers for our groundbreaking longevity and immune resilience observational study.
Receive custom formulations like Retisin + Floristen or Lyastin + Floristen based on your needs.
Access subscription products at reduced rates throughout the study period.
Comprehensive evaluation of your health metrics with personalized insights.
Contribute directly to our validation process and help advance longevity science.
Production and testing are carried out in a certified eco-farm and state-authorized manufacturing facility. All processes are documented, controlled, and compliant with EU food and nutraceutical production standards.
We believe in finishing what others began—with integrity, data, and transparency. RTN's modern revival combines historical insight with today's most advanced tools to bring regenerative immunological/longevity support into the future of healthcare.
Download our whitepaper or contact us directly to explore partnership opportunities.
Join us in reInventedImmunology and see yourself.
RTN Therapeutics s.r.o. | ID: 17380723
Řetouň 66, 400 02 Malečov, Czech Republic
Registered with Regional Court in Ústí nad Labem, File No. C 49191
RTN®, Retisin®, Lyastin®, Floristen®, and Silexil® are registered trademarks of EkoRTN s.r.o.
RTN Therapeutics holds exclusive license for production and distribution of all RTN program outcomes.
© 2022–2025. All rights reserved. All other trademarks mentioned are property of their respective owners.
RTN Therapeutics:
A Scientific Revival